Skip to content

Serotonin: all studies

Page 404 of 408: studies 4,031 to 4,040 of 4,072, newest first. Back to the serotonin overview

Research

Effects on homeostasis of 5-hydroxytryptamine, lysergic acid diethylamide and 2-brom-d-lysergic acid

American Journal of Physiology-Legacy Content December 1, 1959 J. Paul Mcneill, John K. Hampton 3 citations

Rats were injected intramuscularly with 5-HT or LSD and intravenously with 5-HT, LSD, BOL or equimolar concentrations of 5-HT + LSD or 5-HT + BOL. Appropriate saline controls were included. They were then exposed to a standard amount of Noble-Collip trauma. Animals receiving 5-HT i.m. showed a significant multiphasic mortality curve after trauma depending on dose of drug. With small doses,...

Bioassay of Ataractics Against Lethal Action of Mescaline in Mice

Experimental Biology and Medicine July 1, 1958 Nicholas P. Plotnikoff, Helen Washington 7 citations

1. It has been demonstrated that chlorpromazine, perphenazine, proclorperazine, promazine, thiopropazate, promethazine and reserpine are effective antagonists of mescaline-induced mortality in CF1 mice. 2. No significant protection was found with use of sodium phenobarbital, meprobamate, benactyzine, atropine, hydroxyzine, ethoxybutamoxane, SY-21, diphenylhydantoin, trimethadione, lysergic acid...

DOI: 10.3181/00379727-98-24143 (opens in new tab) Mescaline Promethazine Pharmacology Chlorpromazine +11

Effect of Epinephrine on Adrenal Ascorbic Acid Following Premedication With Lysergic Acid Diethylamides or 5-Hydroxyindolalkylamines

Experimental Biology and Medicine June 1, 1958 E. Costa, G. Zetler 7 citations

10 γ/kg i.p. of LSD potentiate the adrenal ascorbic acid depletion caused in rats by 25 γ/kg i.p. of epinephrine, 40 γ/kg i.p. of BOL are ineffective in this respect. 30 γ/kg i.p. of both serotonin and bufotenin potentiate the effects of epinephrine (25 γ/kg i.p.). The threshold doses of bufotenin and serotonin enhancing the epinephrine induced contractions of cat's nictitating membrane were...

Psychopharmacological Studies of Lysergic Acid Diethylamide (LSD-25) Intoxication

A M A Archives of Neurology & Psychiatry December 1, 1957 Lincoln D. Clark 19 citations

One consequence of the recent interest in psychotomimetic drugs has been a search for pharmacological agents that will "block" drug-induced psychological disturbances and hallucinations. Fabing1reported that azacyclonol (Frenquel) in small doses prevented the occurrence of lysergic acid diethylamide (LSD-25) "psychoses" in man, although one of us (L. D. C.) was unable to verify this...

Pharmacology of Lysergic Acid Diethylamide and Some of Its Related CompoundS

Journal of Pharmacy and Pharmacology September 1, 1957 E Rothlin 64 citations

Journal Article Pharmacology of Lysergic Acid Diethylamide and Some of Its Related CompoundS Get access E Rothlin E Rothlin Professor of the University of Basle, Sonnenweg 6, Basle Search for other works by this author on: Oxford Academic Google Scholar Journal of Pharmacy and Pharmacology, Volume 9, Issue 1, September 1957, Pages 569–587, https://doi.org/10.1111/j.2042-7158.1957.tb12312.x...

Some Effects of Bufotenine and Lysergic Acid Diethylamide on the Monkey

Archives of Neurology And Psychiatry 1956 Edward V. Evarts 52 citations

INTRODUCTION Bufotenine (5 -hydroxy -3 -[2- dimethyl-aminoethyl]-indole) is the N-dimethyl derivative of the vasoconstrictor substance serotonin (5-hydroxytryptamine). It was first synthesized by Wieland in 1934. Raymond-Hamet found that intravenous injection of bufotenine caused transient elevation of blood pressure and apnea, followed by tachypnea, in anesthetized dogs.* To date, however,...

Behavioral and Electroencephalographic Effects of Hallucinogenic Drugs

A M A Archives of Neurology & Psychiatry 1956 Bert E. Schwarz 49 citations

Feldberg and Sherwood's* previous studies of the behavior of cats after the intraventricular injection of various drugs opened up a new method of investigation. By this technique they showed that drugs injected into this area of high pharmacologic sensitivity could evoke various complex behavioral responses and conditions resembling sleep, anesthesia, profound muscular weakness, catatonia, and...

Ayahuasca: What Healthcare Providers Need to Know.

Journal of Addictions Nursing Deana Goldin, Deborah Salani 2 citations

Ayahuasca is a pan-Amazonian botanical hallucinogenic decoction made from a mixture of the bark of the Banisteriopsis caapi plant, containing a monoamine oxidase inhibitor, and Psychotria viridis (Rubiaceae) or Diplopterys cabrerana shrubs containing a serotonergic 2A receptor agonist, N,N-dimethyltryptamine, a powerful psychoactive substance. Ayahuasca is a traditional psychoactive sacrament...

The Use of Classic Psychedelics for Depressive and Anxiety-Spectrum Disorders: A Comprehensive Review.

Journal of Clinical Psychopharmacology Vivian Kim, Scott M Wilson, Mary E Woesner 3 citations

Following a decades-long decline in psychedelic research resulting from social, political, and legislative factors, there has been greatly renewed interest in these compounds' ability to treat psychiatric disorders. Classic psychedelics, encompassing both natural and synthetic psychoactive compounds, are characterized by their action as agonists or partial agonists of serotonin...